Soligenix, Inc. Press Releases

SNGX 
$1.68
*  
0.04
2.33%
Get SNGX Alerts
*Delayed - data as of Oct. 20, 2014 14:23 ET  -  Find a broker to begin trading SNGX now


Community Rating:
View:    SNGX Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By
Vista Partners Updates Coverage on Soligenix, Inc. (Ticker: SNGX); Revises Price Target Higher From $5.50 to $7.00
9/24/2014 9:00:00 AM - Market Wire


Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development
9/23/2014 7:00:00 AM - PR Newswire


Soligenix Awarded NIAID Contract Valued up to $24.7 Million for the Development of Heat Stable RiVax™ Vaccine
9/19/2014 7:00:00 AM - PR Newswire


Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma
9/17/2014 7:00:00 AM - PR Newswire


Soligenix Announces Issuance of US Patent for ThermoVax™ Technology
9/9/2014 7:00:00 AM - PR Newswire


Soligenix to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City
9/8/2014 7:00:00 AM - PR Newswire


Soligenix Expands Pipeline with Acquisition of Phase 3-Ready Oncology Clinical Program
9/5/2014 7:00:00 AM - PR Newswire


Soligenix Announces Positive Survival Results with Heat Stable Ricin Toxin Vaccine
9/2/2014 7:00:00 AM - PR Newswire


Rodman & Renshaw 2014 Annual Global Investment Conference to be held in New York from September 8 to 10, 2014
8/11/2014 8:00:00 AM - Business Wire


Soligenix Reports Second Quarter 2014 Financial Results, and Highlights Recent Accomplishments
8/11/2014 7:30:00 AM - PR Newswire


Soligenix Advances Development of a Heat Stable Rapidly Acting Anthrax Vaccine VeloThrax™
8/7/2014 7:00:00 AM - PR Newswire


Soligenix Receives Additional NIAID Funding to Advance Development of OrbeShield™ in GI ARS
8/1/2014 7:30:00 AM - PR Newswire